HYUNDAI BIOSCIENCE CO., LTD. Logo

HYUNDAI BIOSCIENCE CO., LTD.

Develops antiviral and anticancer drugs using a proprietary drug delivery system.

048410 | KO

Overview

Corporate Details

ISIN(s):
KR7048410005
LEI:
Country:
South Korea
Address:
경상북도 김천시 아포읍 아포공단길 106, 김천시

Description

HYUNDAI BIOSCIENCE CO., LTD. is a biotechnology company focused on developing innovative therapeutics using its proprietary drug delivery system (DDS) technology. The company's core science is based on organic-inorganic hybrid technologies designed to safely and effectively deliver active ingredients. Its main development pipeline includes CP-COV03, a broad-spectrum antiviral agent that enhances cellular autophagy to combat viral infections, and Polytaxel, an anticancer drug candidate developed with polymer transfer technologies to reduce toxicity. The company's primary focus is on creating novel treatments for viral diseases and cancer.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-16 00:00
주식등의대량보유상황보고서(일반)
Korean 113.3 KB
2025-09-16 00:00
투자판단관련주요경영사항(임상시험계획변경승인신청) (뎅기 또는 뎅기 유사 질환 환자를 대상으로 CPCOV03의 2/3상 …
Korean 13.7 KB
2025-09-08 00:00
투자판단관련주요경영사항(임상시험계획변경승인) (전립선암 치료제 CPPCA07의 1상 임상시험계획 변경승인)
Korean 12.7 KB
2025-09-02 00:00
투자판단관련주요경영사항(임상시험계획변경승인신청) (전립선암 치료제 CPPCA07의 1상 임상시험계획 변경승인 신청)
Korean 11.6 KB
2025-08-25 00:00
[기재정정]사업보고서 (2024.12)
Korean 1.7 MB
2025-08-25 00:00
[기재정정]분기보고서 (2025.03)
Korean 1.2 MB
2025-08-25 00:00
[기재정정]반기보고서 (2025.06)
Korean 1.2 MB
2025-08-19 00:00
주식등의대량보유상황보고서(일반)
Korean 118.2 KB
2025-08-18 00:00
투자판단관련주요경영사항(임상시험계획자진취하등) (췌장암 치료제 Polytaxel의 1상 임상시험계획 자진취하)
Korean 11.1 KB
2025-08-14 00:00
반기보고서 (2025.06)
Korean 1.2 MB
2025-08-08 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.4 KB
2025-08-01 00:00
임시주주총회결과
Korean 7.5 KB
2025-07-23 00:00
권리락 (무상증자)
Korean 3.5 KB
2025-07-18 00:00
주식등의대량보유상황보고서(일반)
Korean 116.0 KB
2025-07-18 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.6 KB

Automate Your Workflow. Get a real-time feed of all HYUNDAI BIOSCIENCE CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for HYUNDAI BIOSCIENCE CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for HYUNDAI BIOSCIENCE CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.